LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

LeonaBio to Host KOL Event on Lasofoxifene for ER+/HER2- MBC

LeonaBio, Inc. announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, April 29, 2026, to discuss the evolving treatment landscape for metastatic breast cancer and the potential of its lead drug candidate, lasofoxifene. The event will feature leading physician experts in the breast cancer field and highlight lasofoxifene's role in addressing critical unmet needs for patients with treatment-resistant estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated metastatic breast cancer. The company expects to complete enrollment in its ongoing ELAINE-3 Phase 3 registrational study for lasofoxifene in the fourth quarter of 2026, with data anticipated in the second half of 2027.

• LeonaBio's upcoming virtual KOL event on April 29, 2026, will feature discussions with prominent breast cancer experts, including Dr. David Portman, Dr. Matthew P. Goetz, and Dr. Seth Wander. The event aims to explore the current treatment landscape and position lasofoxifene as a potential new standard of care for patients with treatment-resistant ER+, HER2-, ESR1-mutated metastatic breast cancer, addressing persistent gaps in care for genetically defined populations.
• Lasofoxifene is a novel, nonsteroidal selective estrogen receptor modulator (SERM) designed to target both wild-type and mutant estrogen receptors, including ESR1 mutations linked to endocrine therapy resistance. Previous Phase 2 studies, ELAINE-1 and ELAINE-2, demonstrated promising results. ELAINE-1 showed improved median progression-free survival (5.6 vs. 3.7 months) and objective response rates (13.3% vs. 2.9%) compared to fulvestrant, while ELAINE-2, combining lasofoxifene with abemaciclib, achieved a median PFS of approximately 13 months and an ORR of 56% in heavily pretreated patients.
• The ongoing ELAINE-3 (NCT05696626) is a Phase 3 registrational trial evaluating lasofoxifene in combination with abemaciclib for ER+, HER2-, ESR1-mutated metastatic breast cancer patients who have progressed on aromatase and CDK4/6 inhibitors. LeonaBio anticipates completing enrollment in 4Q26 and releasing data in 2H27, aiming to establish a new standard of care. The metastatic breast cancer market, valued at $17.1 billion in 2021, is projected to grow to $41.7 billion by 2030, reflecting a significant opportunity for innovative therapies like lasofoxifene.

Overcoming Resistance: Lasofoxifene's Unique Mechanism Against ESR1 Mutations

Multiple resistance mechanisms have been identified in treatment-resistant ER+, HER2- metastatic breast cancer, with several specifically relevant to ESR1-mutated tumors. The most significant mechanisms include acquired ESR1 mutations that develop in response to endocrine deprivation, leading to constitutive estrogen receptor activation independent of ligand binding. These mutations confer resistance to aromatase inhibitors, selective estrogen receptor modulators, and selective estrogen receptor degraders. Additionally, constitutive activation of cyclin-dependent kinases (CDK) 4 and 6 represents a major resistance pathway, while cross-talk between ER and growth factor receptor signaling, particularly involving HER family members and fibroblast growth factor receptor (FGFR) pathways, enables tumors to bypass endocrine blockade.

Growth and survival signaling through the PI3K/Akt/mTOR pathway constitutes another critical resistance mechanism, often activated when primary endocrine pathways are inhibited. Epigenetic modifications mediated by histone deacetylase (HDAC) can alter gene expression patterns to promote resistance, while interactions between tumor cells and the microenvironment, including immune response modulation, contribute to treatment failure. Notably, protein kinase C alpha (PKCα) overexpression has been specifically associated with antiestrogen resistance, with all resistant cell lines studied showing elevated PKCα levels compared to sensitive parental cells.

The development of resistance frequently involves multiple simultaneous mechanisms, creating a complex therapeutic challenge. Research has revealed that metastatic ER+ breast cancers with endocrine resistance often exhibit acquired genetic alterations and may undergo subtype switching during treatment. Environmental factors such as hypoxic microenvironments further contribute to resistance by reducing ER expression and decreasing sensitivity to hormonal agents. These findings highlight the need for combination therapeutic approaches that can simultaneously target multiple resistance pathways in ESR1-mutated tumors.

Shaping the Future: Lasofoxifene's Role in Evolving MBC Treatment

The treatment landscape for ESR1-mutated metastatic breast cancer has undergone significant transformation with the emergence of next-generation selective estrogen receptor degraders (SERDs) as targeted therapies. The landmark SERENA-6 trial in 2025 demonstrated a paradigm shift by implementing routine ESR1 mutation monitoring during first-line therapy, testing 3,256 patients with ER-positive, HER2-negative advanced breast cancer for circulating tumor DNA mutations every 2-3 months. When ESR1 mutations emerged during aromatase inhibitor plus CDK4/6 inhibitor treatment, patients who switched to camizestrant while continuing their CDK4/6 inhibitor achieved a median progression-free survival of 16.0 months compared to 9.2 months for those maintaining the original regimen (hazard ratio 0.44, P<0.0001).

Complementing this proactive approach, the EMBER-3 phase 3 trial established imlunestrant, a brain-penetrant oral SERD, as an effective treatment specifically for ESR1-mutated disease. Among 256 patients with ESR1 mutations who had progressed on aromatase inhibitor therapy, imlunestrant demonstrated superior efficacy with a median progression-free survival of 5.5 months versus 3.8 months with standard therapy. The combination of imlunestrant with abemaciclib further enhanced outcomes, achieving a median progression-free survival of 9.4 months compared to 5.5 months with imlunestrant monotherapy, regardless of ESR1 mutation status.

These developments represent a fundamental shift from reactive treatment approaches to precision medicine strategies that anticipate and address ESR1-mediated resistance. The integration of routine molecular monitoring with mutation-specific therapeutics has transformed ESR1 mutations from inevitable resistance mechanisms to actionable targets, establishing new standards for managing treatment-resistant ER-positive, HER2-negative metastatic breast cancer while maintaining favorable safety profiles with discontinuation rates below 2% due to adverse events.

Lasofoxifene: A New Horizon for ESR1-Mutated mBC

The landscape of metastatic breast cancer (mBC) treatment is continually evolving, with a growing emphasis on addressing specific mechanisms of resistance. A significant challenge lies in managing estrogen receptor-positive (ER+), HER2-negative disease that has developed acquired ESR1 mutations, a common driver of endocrine resistance following progression on standard therapies like aromatase inhibitors and CDK4/6 inhibitors. This patient population represents a critical unmet need, often facing limited effective oral treatment options.

LeonaBio's lead candidate, lasofoxifene, a novel selective estrogen receptor modulator (SERM), is positioned to directly address this challenge. Data from the Phase 2 ELAINE 1 study demonstrated encouraging antitumor activity in ESR1-mutated mBC patients who had progressed on prior endocrine therapy. While the primary endpoint of progression-free survival (PFS) did not reach statistical significance compared to fulvestrant, lasofoxifene showed numerical advantages across several key efficacy measures, including a higher objective response rate and improved 6-month and 12-month PFS rates. Crucially, the drug also demonstrated target engagement by significantly reducing ESR1 mutant allele fraction, suggesting its mechanism of action is effectively targeting the underlying resistance.

Beyond efficacy, lasofoxifene presents a potential quality-of-life advantage. The ELAINE 1 study revealed that oral lasofoxifene appeared to improve genitourinary syndrome of menopause (GSM) vaginal symptoms, a common and often debilitating side effect of endocrine therapies, whereas fulvestrant was associated with an increase in these symptoms. This differentiation could be a significant factor in patient preference and adherence for a chronic treatment.

However, the path forward is not without considerations. The lack of statistical significance in the Phase 2 PFS endpoint means that the upcoming Phase 3 ELAINE-3 trial, with data anticipated in the second half of 2027, will be pivotal. Robust, statistically significant results will be essential to firmly establish lasofoxifene's clinical differentiation and secure its place in treatment guidelines. Furthermore, while generally well-tolerated, the observed adverse events such as nausea, fatigue, arthralgia, and hot flushes will need careful management in a real-world setting. LeonaBio's proactive KOL event signals confidence and an intent to educate the market on lasofoxifene's potential ahead of these crucial Phase 3 results, aiming to position it as a valuable new oral option for a challenging and underserved patient group.